KPKevin Peng

Kevin Peng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kevin Peng has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hyaluronic acid conjugates for topical treatment of skin cancer lesions

    by Vinu Krishnan, Kevin Peng, Apoorva Sarode, Supriya Prakash, Zongmin Zhao, Sergey K. Filippov, Kristina Todorova, Brittney R. Sell, Omar Lujano, Shirin Bakre, et al.

    Polymer-drug conjugates are developed for the topical ratiometric delivery of a synergistic drug pair to treat skin cancers.


  • Enhancement of Anticancer Efficacy and Tumor Penetration of Sorafenib by Ionic Liquids

    by Yujie Shi, Zongmin Zhao, Kevin Peng, Yongsheng Gao, Debra Wu, Jayoung Kim, Samir Mitragotri

    Ionic liquids (ILs) possess unique solvation and biological properties for drug delivery. Choline and geranic acid (CAGE) in particular, has been successfully formulated to orally deliver insulin and hydrophobic therapeutics such as sorafenib (SRF). However, relatively little is known about the effect of CAGE on intracellular delivery of drugs. Here the effect of low‐concentration CAGE (−1) on the delivery of SRF into cancer cells (4T1, PANC‐1, and HT29) as well as intestine epithelium cells (Caco‐2) is studied. The anti‐cancer effect of SRF is enhanced by up to fivefold in the presence of CAGE (0.5 mg mL−1). The effect is mediated not by enhancing the cellular uptake of SRF but by improving intracellular SRF retention by inhibiting exocytosis. Moreover, CAGE improves the anti‐tumor effect of SRF by increasing apoptosis and blocking cell‐cycle progression. Moreover, CAGE significantly enhances the penetration of SRF into and across multicellular constructs with multiple mechanisms involved. Collectively, the administration of ILs such as CAGE combined with SRF may offer a novel therapy to better inhibit tumor progression.